2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Clinical Procedures, Emerging Technologies, Treatment Considerations, Supportive Care, Biological Therapies, Infusion, Non-Biological Therapies, Anticoagulant Drugs, Coagulant Drugs, Pharmacology, Women’s Health, Workforce, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, VWD, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Neutropenia, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Pregnant, Young Adult
PAPER

2606 Substantial healthcare needs and hospitalization burden in primary warm autoimmune hemolytic anemia (wAIHA): A matched cohort study in the United States

Hanny Al-Samkari, MD, Laurence Pollissard, MS2, Maria Belen Rodriguez, MD3, Kalyani Hawaldar, MS4, Siddhi Umarje, PharmD, ScM5
1 Division of Classical Hematology, Mass General Brigham Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
2 Sanofi, Gentilly, France
3 Sanofi, Cambridge, Massachusetts, United States
4 Sanofi, Washington DC, United States
5 Sanofi, Morristown, New Jersey, United States

Introduction: wAIHA is a rare autoimmune disease characterized by a relapse-remitting course, hemolysis and substantial clinical burden. Currently, no therapies are approved for wAIHA, and management primarily relies on systemic corticosteroids, broad immunosuppressants, splenectomy, and supportive care. Frequent disease monitoring, disease and/or treatment-related complications, and acute disease exacerbations may contribute to considerable healthcare resource utilization (HCRU); however, the magnitude of this burden remains poorly characterized.

Methods: We analyzed STATinMED’s Research Ready Registry, a nationally representative database derived from STATinMED’s RWD insights® (August 2016–October 2023) with Medicaid, Medicare, Medicare Fee-for-Service, Medicare Advantage, and Commercial patients enrolled across the US. We identified 1,642 newly diagnosed primary wAIHA adult patients indexed at first qualifying AIHA/wAIHA diagnosis code and continuously enrolled for ≥1-year before and after index. Patients with secondary wAIHA, cold agglutinin disease, or mixed AIHA were excluded. Each wAIHA patient was matched 1:4 to referent non-wAIHA patients by age, sex, region, insurance type, and index date. An advanced subcohort (n = 517), defined as patients failing ≥1 wAIHA therapy were separately matched 1:4 to non-wAIHA patients. Annual HCRU, including hospitalization, emergency room (ER) and outpatient encounters (in-person, urgent care, laboratory encounters, and virtual care) were assessed. Study outcomes were summarized as the proportion of patient with ≥1 encounter, annual rate of events and rate ratios (RR) with corresponding 95% confidence intervals (CI). wAIHA-related healthcare utilization was also evaluated. Rates and RR were estimated using negative binomial generalized linear models with log link.

Results: Primary wAIHA patients (n = 1,642; mean age: 62.3 years, 61.8% female) had higher baseline comorbidity burden than matched non-wAIHA referents (mean (Standard Deviation; SD) Charlson Comorbidity Index: 1.9 (2.1) vs 0.9 (1.5)) and experienced significantly greater HCRU over 1 year of follow-up from diagnosis. More than half (55.7%) of wAIHA patients required hospitalization (mean rate (95% CI): 1.2 (1.1–1.2) hospitalizations per patient per year (PPPY)) versus 14.2% of non-wAIHA patients (mean rate (95%CI): 0.2 (0.2–0.2) PPPY), corresponding to a 5-fold higher RR (95% CI): 5.0 (4.7– 5.3). ER utilization was also higher, with 37.0% versus 24.0% of wAIHA and non-wAIHA patients, respectively, experiencing ≥1 visit, with rates more than double in wAIHA patients (mean rate (95% CI): 1.1 (1.1–1.2) vs 0.5 (0.5–0.6) visits PPPY, p<0.001; RR (95% CI): 2.1 (2.0–2.3). Outpatient encounters were nearly twice as frequent among wAIHA versus non-wAIHA patients, (mean rate (95% CI): 18.9 (18.7–19.2) vs 11.4 (11.3–11.5) encounters PPPY, p<0.001; RR (95% CI): 1.7 (1.6–1.7)). Resource utilization directly attributable to wAIHA was substantial. wAIHA-related hospitalizations occurred in 29.0% (n = 478) of patients with a mean (SD) of 1.3 (0.6) hospitalizations PPPY and mean (SD) duration of 8.0 (12.5) days per hospitalization. Additionally, 63.0% (n = 1,037) of patients had wAIHA–related outpatient encounters (mean (SD): 4.7 (7.6) encounters PPPY and 8.0% (n = 133) of patients had wAIHA-related ER visits (mean (SD): 2.2 (2.2) visits PPPY). The burden was even greater among advanced wAIHA patients, who experienced higher rates of hospitalization (RR (95% CI): 5.5 (4.9–6.2)), outpatient encounters (RR (95% CI): 2.2 (2.1–2.2)), and ER visits (RR (95% CI): 2.2 (2.0–2.4) relative to matched controls.

Conclusion: Patients with primary wAIHA experienced substantially greater healthcare needs and care intensity than matched non-wAIHA controls, in the US including markedly increased hospitalizations, ER, and outpatient care. The greater burden observed among advanced wAIHA patients further highlights the considerable healthcare requirements associated with wAIHA disease. Together, these findings demonstrate the substantial real-world burden of wAIHA in the US, and underscore the unmet need for safe and effective therapies capable of reducing disease burden and subsequently healthcare needs.

Hanny Al-Samkari, MD: Atavistik - Research Funding; Sanofi - Research Funding; Amgen - Research Funding; SOBI - Research Funding; Novartis - Research Funding; Alnylam - Research Funding; Vaderis - Research Funding; Tectonic - Research Funding; Argenx - Research Funding; Agios Pharmaceuticals - Research Funding; Alpine Immune Sciences - Research Funding; Pharmacosmos - Research Funding; Novartis - Consultancy (Includes expert testimony); Agios Pharmaceuticals - Consultancy (Includes expert testimony); Alnylam - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Argenx - Consultancy (Includes expert testimony); SOBI - Consultancy (Includes expert testimony); Tectonic - Consultancy (Includes expert testimony); Alpine Immune Sciences - Consultancy (Includes expert testimony); Diagonal - Consultancy (Includes expert testimony); Terremoto - Consultancy (Includes expert testimony); Pharmacosmos - Consultancy (Includes expert testimony); Atavistik - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)